Luis Pinana, JoseLopez-Corral, LuciaMartino, RodrigoMontoro, JuanVazquez, LourdesPerez, AriadnaMartin-Martin, GabrielFacal-Malvar, AnaFerrer, ElenaPascual, Maria-JesusSanz-Linares, GabrielaGago, BeatrizSanchez-Salinas, AndresVillalon, LuciaConesa-Garcia, VenancioOlave, Maria T.Lopez-Jimenez, JavierMarcos-Corrales, SaraGarcia-Blazquez, MartaGarcia-Gutierrez, ValentinAngel Hernandez-Rivas, JoseSaus, AnaEspigado, IldefonsoAlonso, CarmenHernani, RafaelSolano, CarlosFerrer-Lores, BlancaGuerreiro, ManuelRuiz-Garcia, MontserratLuis Munoz-Bellido, JuanNavarro, DavidCedillo, AngelSureda, AnnaInfect Complications Subcomm Spani2025-01-072025-01-072021-11-020361-8609https://hdl.handle.net/10668/24349This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopeniaenChronic lymphocytic-leukemiaClinical characteristicsInfluenza vaccinationInfectionsImmunogenicityMalignanciesAdultsresearch article34695229open access10.1002/ajh.263851096-8652https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.26385713672100001